SCHEMBL20972157

SCHEMBL20972157

O=C(Nc1ccc(F)cn1)C1(c2ccc(Br)cc2)CCC1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 5/20 0.52
IDO1 P14902 3/20 0.49
FFAR2 O15552 3/20 0.49
ALDH1A1 P00352 3/20 0.49
HTT P42858 1/20 0.49
ELOVL1 Q9BW60 1/20 0.44
CYP2C9 P11712 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HDAC3 O15379 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30636529 1.00 HDAC1 (0.52) HDAC1IDO1FFAR2ALDH1A1HTT
SCHEMBL20898595 0.86 HDAC1 (0.57) HDAC1IDO1FFAR2ALDH1A1HTT
SCHEMBL20972093 0.86 IDO1 (0.49) HDAC1IDO1ALDH1A1ELOVL1CYP2C9
SCHEMBL30636515 0.86 IDO1 (0.49) HDAC1IDO1ALDH1A1ELOVL1CYP2C9
SCHEMBL20898583 0.83 HDAC1 (0.51) HDAC1IDO1FFAR2ALDH1A1HTT
SCHEMBL9966423 0.82 HDAC1 (0.59) HDAC1IDO1FFAR2ALDH1A1HTT
SCHEMBL9966428 0.81 HDAC1 (0.49) HDAC1FFAR2ALDH1A1HTTELOVL1
SCHEMBL20910441 0.81 HDAC1 (0.70) HDAC1IDO1ALDH1A1CYP2C9NPC1
SCHEMBL9966379 0.81 HDAC1 (0.57) HDAC1FFAR2ALDH1A1HTTCYP2C9
SCHEMBL26000650 0.80 HDAC1 (0.48) HDAC1IDO1FFAR2ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3710444-B1 NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-04-12 EP disclosed
US-10995085-B2 Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors MERCK SHARP & DOHME CORP. (US) 2021-05-04 US disclosed
EP-3710444-A1 NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS Merck Sharp & Dohme Corp. (US) 2020-09-23 EP disclosed
US-20200216425-A1 NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME CORP. (US) 2020-07-09 US disclosed
CN-111344287-A Novel substituted biaryl compounds as indoleamine 2, 3-dioxygenase (IDO) inhibitors 默沙东公司 2020-06-26 CN disclosed
US-10647705-B2 Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors MERCK SHARP & DOHME CORP. (US) 2020-05-12 US disclosed
US-20190144433-A1 NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS MERCK SHARP & DOHME CORP. (US) 2019-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647705-B2 Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors IDO1, IDO2, KYNU HDAC1 75/4885IDO1 1/4885FFAR2 1742/4885
US-20200216425-A1 NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS IDO1, IDO2, KYNU HDAC1 70/4885IDO1 1/4885FFAR2 1631/4885
US-10995085-B2 Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors IDO1, IDO2, KYNU HDAC1 75/4885IDO1 1/4885FFAR2 1742/4885
US-20190144433-A1 NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS IDO1, IDO2, KYNU HDAC1 70/4885IDO1 1/4885FFAR2 1631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.